Truist Lowers Boston Scientific's Price Target Due to Changing Usage Patterns in Heart Device
On June 4, Truist Securities reduced its price target for Boston Scientific (NYSE:BSX) from $85 to $64 while maintaining a 'Buy' rating. The adjustment follows declining demand for the company’s Watchman heart device due to doctors increasingly combining it with other procedures rather than using it as standalone treatment.
Tickers: $BSX
Topics: Healthcare Medical Devices Stock Analysis